Occult tubal carcinoma found at risk reducing salpingectomy in a BRCA1 carrier

Gynecologic Oncology Reports

Volumn 9, Issue , 2014, Pages 1-2

  Kim, Sarah H ^a   Frey, Melissa K ^b   Blank, Stephanie V ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Risk reducing salpingectomy BRCA1 carcinoma

Indexed keywords

BRCA1 PROTEIN; CA 125 ANTIGEN; PLATINUM DERIVATIVE;

ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CASE REPORT; CONSULTATION; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; LYMPH NODE DISSECTION; MULTIPLE CYCLE TREATMENT; OCCULT TUBAL CARCINOMA; OMENTECTOMY; OVARIECTOMY; OVARY CARCINOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SALPINGECTOMY; SURGICAL RISK; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 84899800513     PISSN: None     EISSN: 2211338X     Source Type: Journal    
DOI: 10.1016/j.gynor.2014.03.003     Document Type: Article

References (14)

1. American College of Obstetricians and Gynecologists Elective and risk-reducing salpingo-oophorectomy. ACOG Practice Bulletin No. 89. Obstet. Gynecol. 2008, 111:231-241.
2. American College of Obstetricians and Gynecologists Hereditary breast and ovarian cancer syndrome. ACOG Practice Bulletin No. 103. Obstet. Gynecol. 2009, 113:957-966.
3. Centre Oscar Lambret Radical fimbriectomy for young BRCA mutation carriers. ClinicalTrials.gov [Internet] 2011, National Library of Medicine (US), Bethesda (MD), ([cited 2014 March 19]. Available from: http://clinicaltrials.gov/show/NCT01608074 NLM Identifier: NCT01608074).
4. Crum C.P., McKeon F.D., Xian W. BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis. Int. J. Gynecol. Cancer 2012, 22(1):29-34.
5. Finlayson S. Advocating fallopian tube removal at the time of hysterectomy to prevent ovarian cancer. This changed my practice (UBC CPD). The University of British Columbia, 5 June 2011. Web. 19 March 2014 2011, Available from: http://thischangedmypractice.com/fallopian-tube-removal.
6. Friebel T.M., Domchek S.M., Neuhausen S.L., Wagner T., Evans D.G., Isaacs C., Garber J.E., Daly M.B., Eeles R., Matloff E., Tomlinson G., Lynch H.T., Tung N., Blum J.L., Weitzel J., Rubinstein W.S., Ganz P.A., Couch F., Rebbeck T.R. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin. Breast Cancer 2007, 7:875-882.
7. Herzog T.J., Dinkelspiel H.E. Fallopian tube removal: "STIC-ing" it to ovarian cancer: what is the utility of prophylactic tube removal?. Curr. Oncol. 2013, 20(3):148-151.
8. Kwon J.S., Tinker A., Pansegrau G., McAlpine J., Housty M., McCullum M., Gilks C.B. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet. Gynecol. 2013, 121(1):14-24.
9. M.D.Anderson Cancer Center Prophylactic salpingectomy with delayed oophorectomy. ClinicalTrials.gov [Internet] 2013, fable from: htt Medicine (US), Bethesda (MD), ([cited 2014 March 19]. Available from: http://clinicaltrials.gov/show/NCT01907789 NLM Identifier: NCT01907789).
10. Manchanda R., Abdelraheim A., Johnson M., Rosenthal A.N., Benjamin E., Brunell C., Burnell M., Side L., Gessler S., Saridogan E., Oram D., Jacobs I., Menon U. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG 2011, 118:814-824.
11. Narod S.A. Salpingectomy to prevent ovarian cancer. Curr. Oncol. 2013, 20:145-147.
12. Powell C.B., Chen L., McLennan J., Crawford B., Zaloudek C., Rabban J.T., Moore D.H., Ziegler J. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int. J. Gynecol. Cancer 2011, 21:846-851.
13. Rebbeck T.R., Kauff N.D., Domcheck S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J. Natl. Cancer Inst. 2009, 101:80-87.
14. Vaughan S., Coward J.I., Bast R.C., Berchuck A., Berek J.S., Brenton J., Coukos G., Crum C.C., Drapkin R., Etemadmoghadam D., Friedlander M., Gabra H., Kaye S.B., Lord C.J., Lengyel E., Levine D.A., McNeish I.A., Menon U., Mills G.B., Nephew K.P., Oza A.M., Sood A.K., Stronach E.A., Walczak H., Bowtell D.D., Balkwill F.R. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 2011, 11:719-725.